Showing 1–9 of 15 results
-
AED3,500.00
The 24G Pharmacogenomics plus DNA Test is a cutting-edge genetic analysis that provides personalized insights into drug response and overall health. It examines pharmacogenomics, helping to predict how your body metabolizes medications, reducing adverse drug reactions and optimizing treatment plans. Additionally, it includes a comprehensive DNA test covering traits, wellness, and genetic predispositions. Key benefits include personalized medication guidance, enhanced treatment safety, and actionable health insights.
Sample Type : Saliva
Methodology : Illumina
TAT : 3-6 Weeks
-
AED650.00
Sample Type : Serum
Methodology : Liquid chromatography / Tandem mass spectrometry (LC-TMS/MS)
TAT : 15 Days
-
AED80.00
Sample Type : Serum
Methodology : Spectrophotometry
TAT : 1 Day
-
AED1,150.00
Sample Type : Whole Blood
Methodology : Enzyme-immunoassay
TAT : 10 Days
-
AED4,000.00
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
-
AED1,020.00
Sample Type : Serum
Methodology : Radioimmunoaasay
TAT : 5 weeks
-
AED750.00
Lamotrigine (Lamictal) level testing via HPLC ensures accurate serum analysis for epilepsy & bipolar disorder management. Reliable results for optimal dosing.
Sample Type : Serum
Methodology : HPLC – High Performance Liquid Chromatography / UV detection
TAT : 10 Days
-
AED1,250.00
Sample Type : Serum
Methodology : Photometry
TAT : 15 Days
-
AED35,000.00
The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation.
